Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations analyze observed that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabilit... https://nikoso975osr6.bloggosite.com/profile